AR084195A1 - FORMULATION OF A COMPLEX THAT INCLUDES LERCANIDIPINE CHLORHYDRATE AND VALSARTAN AND METHOD FOR THE PREPARATION OF THE SAME - Google Patents
FORMULATION OF A COMPLEX THAT INCLUDES LERCANIDIPINE CHLORHYDRATE AND VALSARTAN AND METHOD FOR THE PREPARATION OF THE SAMEInfo
- Publication number
- AR084195A1 AR084195A1 ARP110104583A ARP110104583A AR084195A1 AR 084195 A1 AR084195 A1 AR 084195A1 AR P110104583 A ARP110104583 A AR P110104583A AR P110104583 A ARP110104583 A AR P110104583A AR 084195 A1 AR084195 A1 AR 084195A1
- Authority
- AR
- Argentina
- Prior art keywords
- valsartan
- preparation
- lercanidipine
- complex
- chlorhydrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparación de la misma. La composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán de acuerdo con la presente tiene un efecto superior en la prevención y el tratamiento de cardiovasculopatías y sus enfermedades complejas, y reduce los efectos adversos de cada componente. La presente composición comprende clorhidrato de lercanidipina y valsartán en forma separada, a fin de incrementar los índices de disolución de ambos componentes y reducir los efectos adversos.Pharmaceutical composition comprising lercanidipine hydrochloride and valsartan as active components and a method for the preparation thereof. The pharmaceutical composition comprising lercanidipine hydrochloride and valsartan according to the present has a superior effect in the prevention and treatment of cardiovascular diseases and their complex diseases, and reduces the adverse effects of each component. The present composition comprises lercanidipine hydrochloride and valsartan separately, in order to increase the dissolution rates of both components and reduce adverse effects.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100125804 | 2010-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084195A1 true AR084195A1 (en) | 2013-04-24 |
Family
ID=46207595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104583A AR084195A1 (en) | 2010-12-09 | 2011-12-07 | FORMULATION OF A COMPLEX THAT INCLUDES LERCANIDIPINE CHLORHYDRATE AND VALSARTAN AND METHOD FOR THE PREPARATION OF THE SAME |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP2648730A4 (en) |
KR (1) | KR101414814B1 (en) |
CN (1) | CN103249415B (en) |
AR (1) | AR084195A1 (en) |
AU (1) | AU2011339150B2 (en) |
BR (1) | BR112013013415A2 (en) |
CL (1) | CL2013001626A1 (en) |
CO (1) | CO6721030A2 (en) |
DO (1) | DOP2013000115A (en) |
EA (1) | EA201390844A1 (en) |
IL (1) | IL226449A0 (en) |
MX (1) | MX2013005716A (en) |
PE (1) | PE20140699A1 (en) |
SG (1) | SG190326A1 (en) |
UA (1) | UA108277C2 (en) |
UY (1) | UY33772A (en) |
WO (1) | WO2012077968A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102755322B (en) * | 2012-07-24 | 2013-12-11 | 兆科药业(广州)有限公司 | Compound preparation of lercanidipine and atorvastatin |
WO2014142521A1 (en) * | 2013-03-12 | 2014-09-18 | 주식회사 엘지생명과학 | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
WO2019008485A1 (en) | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | Fixed dose pharmaceutical composition of valsartan and sacubitril |
KR102233986B1 (en) * | 2019-06-25 | 2021-03-30 | 경남과학기술대학교 산학협력단 | Solid pharmaceutical composition comprising lafutidine and irsogladin and process for producing thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
MXPA06006118A (en) * | 2003-12-01 | 2006-08-11 | Lifecycle Pharma As | Pharmaceutical compositions comprising lercanidipine. |
WO2007001067A2 (en) | 2005-06-27 | 2007-01-04 | Daiichi Sankyo Company, Limited | Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker |
KR100888131B1 (en) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | Combination preparation for Cardiovascular disease therapy by Chronotherapy theory. |
-
2011
- 2011-12-06 UY UY0001033772A patent/UY33772A/en not_active Application Discontinuation
- 2011-12-07 CN CN201180058951.9A patent/CN103249415B/en active Active
- 2011-12-07 EA EA201390844A patent/EA201390844A1/en unknown
- 2011-12-07 AU AU2011339150A patent/AU2011339150B2/en active Active
- 2011-12-07 SG SG2013038211A patent/SG190326A1/en unknown
- 2011-12-07 AR ARP110104583A patent/AR084195A1/en unknown
- 2011-12-07 EP EP11847739.7A patent/EP2648730A4/en not_active Withdrawn
- 2011-12-07 UA UAA201307936A patent/UA108277C2/en unknown
- 2011-12-07 WO PCT/KR2011/009413 patent/WO2012077968A2/en active Application Filing
- 2011-12-07 PE PE2013001346A patent/PE20140699A1/en not_active Application Discontinuation
- 2011-12-07 MX MX2013005716A patent/MX2013005716A/en unknown
- 2011-12-07 BR BR112013013415A patent/BR112013013415A2/en not_active IP Right Cessation
- 2011-12-07 KR KR1020110130400A patent/KR101414814B1/en active IP Right Grant
-
2013
- 2013-05-20 IL IL226449A patent/IL226449A0/en unknown
- 2013-05-21 DO DO2013000115A patent/DOP2013000115A/en unknown
- 2013-06-06 CL CL2013001626A patent/CL2013001626A1/en unknown
- 2013-06-21 CO CO13147794A patent/CO6721030A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112013013415A2 (en) | 2019-09-24 |
DOP2013000115A (en) | 2014-07-31 |
CL2013001626A1 (en) | 2013-10-04 |
EP2648730A2 (en) | 2013-10-16 |
KR20120089787A (en) | 2012-08-13 |
PE20140699A1 (en) | 2014-06-13 |
EA201390844A1 (en) | 2013-11-29 |
UY33772A (en) | 2012-07-31 |
CN103249415A (en) | 2013-08-14 |
UA108277C2 (en) | 2015-04-10 |
SG190326A1 (en) | 2013-06-28 |
IL226449A0 (en) | 2013-07-31 |
WO2012077968A3 (en) | 2012-07-26 |
AU2011339150B2 (en) | 2015-09-10 |
EP2648730A4 (en) | 2014-08-06 |
CO6721030A2 (en) | 2013-07-31 |
WO2012077968A2 (en) | 2012-06-14 |
CN103249415B (en) | 2017-12-12 |
AU2011339150A1 (en) | 2013-06-06 |
KR101414814B1 (en) | 2014-07-21 |
MX2013005716A (en) | 2013-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015002164A1 (en) | Combined formulation of two antiviral compounds. | |
EA201690223A1 (en) | FACTOR INHIBITORS IN THE COMPLEMENT BASED ON PIPERIDININILINDOL DERIVATIVES AND THEIR APPLICATION | |
EA201390804A1 (en) | DOSAGE FORM LACOSAMIDE FOR ADMISSION ONCE IN DAY | |
ECSP11011278A (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES DERIVATIVES OF GLUCOPIRANOSIL DIFENYLMETHANE, PHARMACEUTICAL FORM OF THE SAME, PROCEDURE FOR THEIR PREPARATION AND USES OF THE SAME FOR IMPROVED GLUCEMIC CONTROL IN A PATIENT. | |
MX346224B (en) | Compostions and methods for treating chronic inflammation and inflammatory diseases. | |
UY33183A (en) | INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT | |
CL2015002733A1 (en) | Pharmaceutical composition of s-ketamine hydrochloride. | |
EA201301240A1 (en) | POLYMORPHIC FORMULA BENZOA LIGNOGLIPTINA | |
EA201501024A1 (en) | COMPOSITIONS WITH A DELAYED DELAY, CONTAINING COLCHICIN, AND METHODS OF THEIR APPLICATION | |
BR112015011430A2 (en) | composition for immediate and prolonged release | |
UY31922A (en) | COMPOUNDS | |
GT201500035A (en) | ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS | |
UA113962C2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT | |
DOP2015000071A (en) | COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN, AND METHOD FOR PREPARATION | |
BR112015010271A8 (en) | Comicronization product, process for the preparation of a comicronization product, pharmaceutical composition and its uses | |
DOP2013000115A (en) | FORMULATION OF A COMPLEX THAT INCLUDES LERCANIDIPINE AND VALSARTAN CHLORHYDRATE AND METHOD FOR THE PREPARATION OF THE SAME | |
CO2018004665A2 (en) | Oxadiazoespiric compounds | |
BR112014004737A2 (en) | Ambroxol Hydrochloride Compound Compound and Method of Preparation of Compound | |
GR1008228B (en) | Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof | |
UY34080A (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES FEXOFENADINE AND PREPARATION METHODS | |
IL236562A0 (en) | Pharmaceutical composition having improved flowability, medicinal agent, and method for producing and using same | |
WO2013033602A3 (en) | Fatty acid amides, compositions and methods of use | |
BR112013025610A2 (en) | use of a live avian metapneumovirus and pharmaceutical composition | |
CL2015000778A1 (en) | Synergistic oral pharmaceutical composition comprising nitazoxanide and mebendazole; Preparation process; and use to treat human parasitosis caused by protozoa and helminths. | |
IN2013MU03428A (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |